QGEN
Qiagen
October 2, 2026 · market open
- Rarity
- 2.05
- Peak move
- +7.99%
- Float cap
- $8.6B
Qiagen is a Netherlands-based life sciences and molecular diagnostics company that sells sample-preparation technologies, assays, instruments and bioinformatics software for isolating and analyzing DNA, RNA and proteins from blood, tissue and other materials. It serves over 500,000 customers, including academic and pharmaceutical research laboratories, clinical healthcare providers, and applied-testing markets such as forensics and food safety. Its main franchises include QuantiFERON latent-tuberculosis testing, QIAstat-Dx syndromic panels and QIAcuity digital PCR.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
3 events · 0 from SEC or newswire · 0 timed with the moveinstitutional_flowThe Dutch AFM published a voting-rights notification showing Bank of America Corporation held 5.15% of QIAGEN N.V.'s capital and voting rights as of a September 25, 2026 transaction, held indirectly via Merrill Lynch International and other BofA entities.
regulatory_approvalThe U.S. FDA cleared QIAGEN's QIAstat-Dx BCID GN Plus AMR Panel, a one-hour test detecting 13 gram-negative bacterial targets and 18 antibiotic resistance markers from positive blood cultures, completing the company's U.S. QIAstat-Dx bloodstream infection portfolio.
institutional_flowBlackRock notified the Dutch AFM of a change in its QIAGEN N.V. holding, with a transaction dated September 23, 2026, holding roughly 11.6% of capital interest and 13.0% of voting rights indirectly via ordinary shares and contracts for difference.